LIVE BROADCAST: A New Targeted Therapy For Ovarian Cancer

Article

In an upcoming broadcast, key opinion leaders will discuss clinical efficacy and safety data for a new targeted therapy.

To explore unmet needs for patients with ovarian cancer and obtain expert perspective, watch the live broadcast on 12/14, 6:00pm EST, 12/15, 7:00pm EST and 1/12/23, 8:00pm EST. To register for the event, visit https://studio.mjhassoc.com/reach/National-Broadcast.

US-UNB-2200017 10/22

Related Videos
Video 10 - "Monitoring and AE Management Strategies with Fruquintinib in CRC"
Video 9 - "FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC"
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Annie Im, MD, FASCO
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai